Amneal Expects Fiscal Year 2024 Adjusted EBITDA Of $580M-$620M, With Operating Cash Flow Of $260M-$300M And Capital Expenditures Of $60M-$70M Compared To $558M, $346M, and $43M In 2023, Respectively
Portfolio Pulse from Benzinga Newsdesk
Amneal forecasts an increase in its FY 2024 Adjusted EBITDA to $580M-$620M from $558M in 2023. Operating cash flow is expected to be $260M-$300M, down from $346M, and capital expenditures are projected at $60M-$70M, up from $43M.
March 01, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amneal anticipates a rise in FY 2024 Adjusted EBITDA to $580M-$620M, with a decrease in operating cash flow and an increase in capital expenditures.
The projected increase in Adjusted EBITDA for FY 2024 suggests a positive outlook on Amneal's profitability, which could lead to a positive investor sentiment and potentially increase the stock price in the short term. However, the decrease in operating cash flow and increase in capital expenditures indicate significant reinvestment and operational adjustments, which could temper some of the positive sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100